四精丸通过肠骨轴调节PGE2/EP4/PI3K-AKT通路治疗绝经后骨质疏松症

Sijing Pill modulates PGE2/EP4/PI3K-AKT pathway via gut-bone axis to treat postmenopausal osteoporosis.

作者信息Xiaojuan Zhu, Yufen Li, Xianting Meng, Tao Jiang, Chenhao Li, Xiujing Zhu, Zixin Yin, Junpeng Guo, Xin Su
PMID41929685
发布时间2026-03-18
DOI10.3389/fmicb.2026.1786197

实验完整度

高

包含OVX大鼠模型、16S rRNA测序、非靶向代谢组学、网络药理学、分子对接与动力学模拟,并经Western blot和免疫组化验证。

主要模型

去卵巢(OVX)大鼠模型 Sprague Dawley大鼠

重点核对

OVX大鼠模型,雌性SD大鼠,3月龄,体重220±20g SJP剂量:高剂量11.4g/kg/天,中剂量5.7g/kg/天,低剂量2.85g/kg/天,灌胃给药12周 阳性对照:阿仑膦酸钠(ALN)0.16mg/mL,灌胃给药 16S rRNA测序和粪便非靶向代谢组学每组5个样本 Western blot检测PI3K、p-PI3K、AKT、p-AKT、ZO-1、Occludin

摘要

Introduction: Postmenopausal osteoporosis (PMOP) represents a substantial clinical burden for aging women worldwide. Existing pharmacotherapies are frequently constrained by suboptimal efficacy, poor adherence, and adverse effects, underscoring the need for superior treatment alternatives. The Sijing Pill (SJP) has shown potential in alleviating bone loss in PMOP. However, the fundamental mechanisms underlying its therapeutic effects remain incompletely elucidated, which has impeded its clinical translation and rational application.Methods: The therapeutic effect of SJP on PMOP was first evaluated in ovariectomized (OVX) rat models using hematoxylin and eosin (H&E) staining, micro-computed tomography (μCT), and immunohistochemistry. To investigate the mechanisms, we employed an integrated strategy that combined network pharmacology, molecular docking and dynamics simulations, 16S rRNA sequencing, as well as non-targeted metabolomics coupled with MetOrigin analysis. The key predictions from these analyses were subsequently validated by Western blot and immunohistochemistry.Results: This research confirms that SJP treatment significantly alleviates abnormal weight gain and bone structural degeneration in OVX model mice. Employing an integrated multi-omics strategy, we elucidated a dual mechanism underlying the efficacy of SJP. This mechanism involves the concurrent modulation of the arachidonic acid-PGE2 metabolic axis, which ameliorates osteometabolic inflammation, alongside the remodeling of the gut microbiota, as evidenced by a decreased Firmicutes/Bacteroidetes ratio. Collectively, these factors orchestrate therapeutic effects through the gut-bone axis. Network pharmacology identified 18 bioactive components in SJP with predicted affinities for key signaling nodes, including STAT3, ESR1, and AKT1. Molecular docking confirmed high-affinity binding for pivotal pairs. Specifically, strong binding was observed between Ellipticine and COX2 (-10.6 kcal/mol) and between estrone and PTGES (-7.8 kcal/mol), implicating both in PGE2 metabolism. Functionally, SJP promoted intestinal barrier repair by upregulating ZO-1 and Occludin. In parallel, it activated the bone-specific PGE2-EP4 receptor axis and downstream PI3K-AKT signaling, thereby elucidating a direct mechanistic link through the gut-bone axis.Conclusion: Sijing Pill modulates the PGE2/EP4/PI3K-AKT signaling pathway via the gut-bone axis to aid in alleviating PMOP.

实验结论

提炼研究问题、关键发现与证据,快速把握文章的核心贡献。

研究问题
四精丸(SJP)如何通过肠骨轴调节PGE2/EP4/PI3K-AKT信号通路来治疗绝经后骨质疏松症(PMOP)?
核心机制
SJP通过调节肠道菌群(降低Firmicutes/Bacteroidetes比值)改善肠道屏障功能,并通过花生四烯酸-PGE2代谢轴激活骨特异性PGE2-EP4受体及下游PI3K-AKT信号,从而促进成骨细胞活性,减轻骨丢失。
主要证据
OVX大鼠模型中,SJP显著减轻骨丢失,改善骨微结构,上调RUNX2、OCN、PINP、BMP2,降低TRACP5b;16S rRNA测序显示SJP恢复肠道菌群平衡;代谢组学显示SJP逆转花生四烯酸代谢异常;Western blot和免疫组化显示SJP上调ZO-1、Occludin、EP4、p-PI3K、p-AKT。
研究意义
SJP作为多靶点治疗PMOP的候选药物,其PGE2-EP4-PI3K-AKT信号轴为代谢性骨病研究提供了靶点。

研究路径

按研究推进顺序梳理实验设计、验证步骤与关键观察。

1

OVX大鼠模型建立与分组给药

模拟绝经后骨质疏松症并评估SJP的治疗效果

48只SPF级雌性SD大鼠分为Sham组和OVX组,OVX组行双侧卵巢切除术,术后1周开始灌胃给药,SJP高、中、低剂量及ALN组持续12周。

2

骨组织形态与微结构分析

评估SJP对骨丢失和骨微结构的影响

采用H&E染色和μCT成像分析股骨组织,量化骨小梁面积、骨密度、骨体积分数等参数。

3

骨形成与炎症标志物检测

评估SJP对成骨活性和系统性炎症的影响

通过ELISA检测血清中PINP、BMP2、TRACP5b及炎症因子IL-10、IL-1β、TNF-α的水平。

4

肠道菌群16S rRNA测序分析

分析SJP对OVX大鼠肠道菌群结构和多样性的影响

提取粪便DNA,扩增16S rRNA V3-V4区域,测序后用QIIME2分析α多样性、β多样性、LEfSe差异分析。

5

粪便非靶向代谢组学分析

鉴定SJP调节的差异代谢物及相关通路

利用UHPLC-Orbitrap Q Exactive HF-X质谱检测粪便代谢物,进行PCA/OPLS-DA分析,筛选差异代谢物,并进行KEGG通路富集。

6

网络药理学与分子对接

预测SJP活性成分及其治疗PMOP的潜在靶点

通过TCMSP等数据库筛选SJP活性成分,与PMOP靶点取交集,构建PPI网络,鉴定核心靶点,并进行分子对接和动力学模拟。

7

Western blot和免疫组化验证

验证SJP对肠道屏障和骨PGE2-EP4-PI3K-AKT通路蛋白表达的影响

Western blot检测回肠组织中ZO-1、Occludin及骨组织PI3K、AKT的磷酸化水平;免疫组化检测骨组织中EP4、RUNX2、OCN表达。

8

关联分析

探讨肠道菌群、代谢物、炎症及骨代谢指标之间的关联

对肠道菌群丰度、PGE2等代谢物、TNF-α等炎症因子、EP4和PI3K-AKT通路相关蛋白进行Spearman相关分析。

研究方法

按研究目的归类文中使用的方法,便于定位所需技术。

产品清单

实验环节名称品牌货号
MagPure土壤DNA提取试剂盒Magan--
NanoDrop 2000分光光度计Thermo Fisher--
Qubit双链DNA检测试剂盒----
Takara Ex Taq聚合酶----
Vanquish超高效液相色谱仪----
Orbitrap Q Exactive HF-X质谱仪----
Hypersil Gold色谱柱----
PI3K抗体Proteintech--
AKT抗体Proteintech--
p-AKT抗体Proteintech--
GAPDH抗体Proteintech--
ZO-1抗体Proteintech--
Occludin抗体Proteintech--
p-PI3K抗体Bioss--
OCN抗体Servicebio--
RUNX2抗体Servicebio--
EP4抗体Servicebio--
HRP标记二抗Servicebio--
ELISA试剂盒(检测PINP、BMP2、TRACP5b、TNF-α、IL-1β、IL-10)Nanjing Jiancheng Bioengineering Institute--

关键环节

汇总复现实验时建议重点确认的条件及原文阅读提示。

环节核对要点
动物模型与给药
OVX大鼠模型,SD品系,3月龄,体重220±20g,阴道涂片或激素确认去势成功的标准;SJP剂量(11.4、5.7、2.85g/kg/天)以及给药频率和周期;ALN剂量和给药方式
阅读提示:见Materials and Methods 2.5动物饲养与分组
骨形态学检测
H&E染色步骤(脱钙液、脱水、包埋等)及μCT扫描参数(电压、电流、体素),图像分析软件版本
阅读提示:见Materials and Methods 2.7和2.8
肠道菌群分析
16S rRNA测序使用的DNA提取试剂盒、PCR引物序列、扩增区域V3-V4;每组的样本数(n=5)
阅读提示:见Materials and Methods 2.10
代谢组学分析
样本处理方法(液氮和甲醇)、色谱柱型号、质谱参数;差异代谢物筛选阈值(VIP>1, p<0.05, FC≥2或≤0.25)
阅读提示:见Materials and Methods 2.11
Western blot
抗体详细信息(货号、品牌):PI3K、AKT、p-AKT、ZO-1、Occludin、p-PI3K;蛋白上样量和转膜条件
阅读提示:见Materials and Methods 2.15
免疫组化
一抗浓度和孵育条件;EP4、RUNX2、OCN抗体货号;信号定量方法(ImageJ,每个样本6个HPF)
阅读提示:见Materials and Methods 2.16